Evidence map›Paper›PMID 22666329›Full record

ArticlePloS one2012

Cloning and functional studies of a splice variant of CYP26B1 expressed in vascular cells.

Ali Ateia Elmabsout, Ashok Kumawat, Patricia Saenz-Méndez, Olesya Krivospitskaya, Helena Sävenstrand, Peder S Olofsson, Leif A Eriksson, Ake Strid, Guro Valen, Hans Törmä and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Ali Ateia ElmabsoutDepartment of Clinical Medicine, School of Health Sciences, Örebro University, Örebro, Sweden.
Ashok Kumawat
Patricia Saenz-Méndez
Olesya Krivospitskaya
Helena Sävenstrand
Peder S Olofsson
Leif A Eriksson
Ake Strid
Guro Valen
Hans Törmä
Allan Sirsjö
Örebro University · SECentro Uruguayo de Imagenología Molecular · UYNorthwell Health · USUniversity of Gothenburg · SEUniversity of Oslo · NOUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAll-trans retinoic acid (atRA) plays an essential role in the regulation of gene expression, cell growth and differentiation and is also important for normal cardiovascular development but may in turn be involved in cardiovascular diseases, i.e. atherosclerosis and restenosis. The cellular atRA levels are under strict control involving several cytochromes P450 isoforms (CYPs). CYP26 may be the most important regulator of atRA catabolism in vascular cells. The present study describes the molecular cloning, characterization and function of atRA-induced expression of a spliced variant of the CYP26B1 gene. METHODOLOGY/PRINCIPAL

findingsThe coding region of the spliced CYP26B1 lacking exon 2 was amplified from cDNA synthesized from atRA-treated human aortic smooth muscle cells and sequenced. Both the spliced variant and full length CYP26B1 was found to be expressed in cultured human endothelial and smooth muscle cells, and in normal and atherosclerotic vessel. atRA induced both variants of CYP26B1 in cultured vascular cells. Furthermore, the levels of spliced mRNA transcript were 4.5 times higher in the atherosclerotic lesion compared to normal arteries and the expression in the lesions was increased 20-fold upon atRA treatment. The spliced CYP26B1 still has the capability to degrade atRA, but at an initial rate one-third that of the corresponding full length enzyme. Transfection of COS-1 and THP-1 cells with the CYP26B1 spliced variant indicated either an increase or a decrease in the catabolism of atRA, probably depending on the expression of other atRA catabolizing enzymes in the cells. CONCLUSIONS/SIGNIFICANCE: Vascular cells express the spliced variant of CYP26B1 lacking exon 2 and it is also increased in atherosclerotic lesions. The spliced variant displays a slower and reduced degradation of atRA as compared to the full-length enzyme. Further studies are needed, however, to clarify the substrate specificity and role of the CYP26B1 splice variant in health and disease.

Indexed as

Gene Expression Regulation, EnzymologicAmino Acid SequenceAnimalsAortaAtherosclerosisChlorocebus aethiopsCloning, MolecularCOS CellsCytochrome P-450 Enzyme SystemExonsHumansMolecular Sequence DataMuscle, Smooth, VascularProtein IsoformsRetinoic Acid 4-HydroxylaseTretinoinCytochrome P-450 Enzyme SystemProtein IsoformsRetinoic Acid 4-HydroxylaseTretinoin

Identifiers

PMID22666329
PMCPMC3362586
OpenAlexW2022550506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.